Thinking of joining a study?

Register your interest

Become a volunteer?

NCT07008963 | RECRUITING | Metastatic Breast Cancer

Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant
Sponsor:

AstraZeneca

Brief Summary:

A cross-sectional, non-interventional, observational study using qualitative patient interviews to explore patient experiences and attitudes toward taking capivasertib + fulvestrant as directed

Condition or disease

Metastatic Breast Cancer

Intervention/treatment

non-interventional

Study Type : OBSERVATIONAL
Estimated Enrollment : 50 participants
Official Title : A Non-interventional, Observational Qualitative Interview Study of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant
Actual Study Start Date : 2025-07-31
Estimated Primary Completion Date : 2025-12-31
Estimated Study Completion Date : 2025-12-31

Information not available for Arms and Intervention/treatment

Ages Eligible for Study:
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion criteria (self-reported)
  • * Adult (over the age of 18 years)
  • * Diagnosed with HR+/HER2- metastatic breast cancer
  • * Received at least 1 week of capivasertib + fulvestrant (Patients will be invited to provide documents demonstrating the use of capivasertib. Patients will be able to participate even if unable to obtain such documentation)
  • Exclusion criteria (self-reported)
    • * Patients who had discontinued capivasertib for more than 6 months before the date of the interview
    • * Unable or unwilling to follow study procedures (including providing informed consent)
    • * Not proficient in spoken English, as assessed by the moderator
    • * Receiving capivasertib in a clinical trial setting
    • * Patients who are not able to recall instruction for administration of capivasertib in a manner consistent with the labeling (e.g. 4 days on followed by 3 days off)
Interview of Patients With HR+/HER2- Metastatic Breast Cancer Who Received Capivasertib + Fulvestrant

Location Details

NCT07008963

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United States, California

Research Site

Redwood Shores, California, United States, 94065